Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THROMBOLYSIS IN THROMBOEMBOLIC DISEASES
Autore:
GULBA DC; DECHEND R;
Indirizzi:
UKRV,FRANZ VOLHARD HOSP,WILTBERGSTR 50 D-13125 BERLIN GERMANY MAX DELBRUCK CTR MOLEC MED D-13125 BERLIN GERMANY
Titolo Testata:
Annals of hematology
fascicolo: 4, volume: 69, anno: 1994,
pagine: 190000041 - 190000057
SICI:
0939-5555(1994)69:4<190000041:TITD>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; TISSUE PLASMINOGEN-ACTIVATOR; RENAL-ARTERY EMBOLISM; LEFT-VENTRICULAR FUNCTION; ACUTE PULMONARY-EMBOLISM; LOW-DOSE STREPTOKINASE; LOCAL INTRAARTERIAL FIBRINOLYSIS; RANDOMIZED CONTROLLED TRIAL; BJORK-SHILEY PROSTHESIS; VENA-CAVA FILTER;
Keywords:
THROMBOSIS; EMBOLISM; THROMBOLYSIS; THROMBOLYTIC AGENTS; THROMBOEMBOLIC DISEASE; ANTICOAGULATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
170
Recensione:
Indirizzi per estratti:
Citazione:
D.C. Gulba e R. Dechend, "THROMBOLYSIS IN THROMBOEMBOLIC DISEASES", Annals of hematology, 69(4), 1994, pp. 190000041-190000057

Abstract

Thrombolysis in many manifestations of thromboembolic disease offers a valuable alternative to surgery. However, as thrombolysis is always associated with a bleeding hazard (though low) one should always weighthe risks against the expected benefits when the decision for or against this therapeutic option is made. Furthermore, in selecting the appropriate thrombolytic agent, one should be led by the urgency of reperfusion to maintain organ function. If one decides on an aggressive, high-dose, brief-duration regimen, reperfusion may be achieved more rapidly but may be incomplete in the majority of cases. On the other hand,by selecting an intermediate- or long-duration, low-dose regimen, reperfusion may happen too late to improve the patient's prognosis. Aboveall, one should keep in mind that the hazard of serious bleeding constantly increases with duration of thrombolysis. No matter which strategy is regarded as the best to resolve a clot in a particular patient with a particular type of thromboembolic disease, thrombolysis should be accompanied by high doses of i.v. heparin. Finally, if bleeding occurs in spite of all precautions taken, the new generation of fibrin-specific thrombolytic agents offers the advantage of short half-lives. Inaddition - in contrast to streptokinase - the hemostatic defect that they cause may be rapidly reversed by the infusion of antagonistic drugs such as aprotinin, tranexamic acid, or epsilon-aminocaproic acid. This adds to the clinical safety profile of these thrombolytic agents.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 18:38:44